title: Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
abstract: BACKGROUND
  Vasodilatory therapy of Raynaud's phenomenon represents a difficult clinical problem because treatment often remains inefficient and may be not tolerated because of side effects.
  
  
  RESULTS
  To investigate the effects of sildenafil on symptoms and capillary perfusion in patients with Raynaud's phenomenon, we performed a double-blinded, placebo-controlled, fixed-dose, crossover study in 16 patients with symptomatic secondary Raynaud's phenomenon resistant to vasodilatory therapy. Patients were treated with 50 mg sildenafil or placebo twice daily for 4 weeks. Symptoms were assessed by diary cards including a 10-point Raynaud's Condition Score. Capillary flow velocity was measured in digital nailfold capillaries by means of a laser Doppler anemometer. While taking sildenafil, the mean frequency of Raynaud attacks was significantly lower (35+/-14 versus 52+/-18, P=0.0064), the cumulative attack duration was significantly shorter (581+/-133 versus 1046+/-245 minutes, P=0.0038), and the mean Raynaud's Condition Score was significantly lower (2.2+/-0.4 versus 3.0+/-0.5, P=0.0386). Capillary blood flow velocity increased in each individual patient, and the mean capillary flow velocity of all patients more than quadrupled after treatment with sildenafil (0.53+/-0.09 versus 0.13+/-0.02 mm/s, P=0.0004). Two patients reported side effects leading to discontinuation of the study drug.
  
  
  CONCLUSIONS
  Sildenafil is an effective and well-tolerated treatment in patients with Raynaud's phenomenon.
authors.affiliation: Klinik für Innere Medizin III (Kardiologie, Angiologie, Internistische Intensivmedizin), Universitätsklinikum des Saarlandes, Homburg/Saar, Germany. r.fries@gotthard-schettler-klinik.de
authors.forename: Roland
authors.initials: R
authors.lastname: Fries
authors.forename: Kaveh
authors.initials: K
authors.lastname: Shariat
authors.forename: Hubertus
authors.initials: H
authors.lastname: von Wilmowsky
authors.forename: Michael
authors.initials: M
authors.lastname: Böhm
mesh_terms: D000328:Adult; D000368:Aged; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D003240:Connective Tissue Diseases / Q000150:complications; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011687:Purines; D011928:Raynaud Disease / Q000188:drug therapy* / Q000503:physiopathology; D012595:Scleroderma, Systemic / Q000150:complications; D000068677:Sildenafil Citrate; D013450:Sulfones; D016896:Treatment Outcome; D014664:Vasodilation; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate